# Progress Note 05 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sir John Franklin (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EX005-SYN-TD
- Date: 1845-03-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Cordelia Ashby-Nwankwo, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Preventive Visit
- Services: CPT 99396 (periodic preventive medicine, established patient, age 40 to 64) with CPT 99497 (advance care planning), both on the same day

## Chief complaint

Periodic adult preventive visit before a multi-year Arctic expedition. **S**

## History of present illness

Sir John is a 58-year-old naval officer with stage 2 hypertension on amlodipine, class 1 obesity, mild noise-induced hearing loss and vitamin D insufficiency on vitamin D3, who is preparing to command an Arctic expedition expected to last two to three years, and comes for his preventive visit two weeks after his four-week review. He has recovered from influenza except for a dry cough on cold mornings, and he walks three to four miles a day again. His home readings this week average 131/81. He has lost 2.4 kg since intake by walking, hill climbing and smaller portions. His dentist examined him last week, took films and replaced a cracked filling. He had influenza and COVID-19 vaccines in the autumn and his last tetanus booster was more than ten years ago; he has never had pneumococcal, zoster, hepatitis B or rabies vaccines. He has never had colorectal cancer screening. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 58, nine weeks before sailing |
| Blood pressure | Home average 131/81 on amlodipine 5 mg |
| Weight | 88.4 kg, from 90.8 at intake |
| Mood | PHQ-2 0 |
| Medicines | Amlodipine 5 mg daily; vitamin D3 25 micrograms daily |

## Health risk assessment

Completed by the patient on paper in the waiting room and reviewed with him by Dr. Ashby-Nwankwo. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Good; better since the influenza passed |
| Psychosocial | Married; busy with the expedition's preparations; the end of his last post still weighs on him, and he sees the command as a chance to set that right |
| Alcohol | One glass of wine with dinner on most days, down from two; AUDIT-C 3 at intake |
| Tobacco | Never |
| Physical activity | Walks three to four miles a day, with hills twice a week |
| Nutrition | Smaller portions, more vegetables and fruit, less salt and fewer puddings |
| Sleep | Seven hours; no snoring reported, no daytime sleepiness |
| Safety | Wears a seat belt; no firearms at home; uses hearing protection on the gun deck |
| Activities of daily living | Independent |
| Hearing and vision | Trouble hearing in noisy rooms; reading glasses; eye examination last year |
| Oral health | Dental examination and a replaced filling last week |
| Travel | Two to three years in the Arctic with no outside contact; ship's surgeons on board; no evacuation possible for months at a time |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy back; weight down 2.4 kg by intention |
| Eyes | Negative | No change in vision |
| Ears, nose, mouth, and throat | Positive | Trouble hearing in noisy rooms, unchanged |
| Cardiovascular | Negative | No chest pain, palpitations or ankle swelling |
| Respiratory | Positive | Dry cough on cold mornings, fading; no breathlessness |
| Gastrointestinal | Negative | No bleeding, change in bowel habit or indigestion |
| Genitourinary | Negative | Gets up once at night to pass urine; no hesitancy |
| Musculoskeletal | Negative | Mild knee stiffness after hills; no joint swelling |
| Integumentary | Negative | No new skin lesions |
| Neurological | Negative | No numbness, weakness or headaches |
| Psychiatric | Negative | Mood good; PHQ-2 0 |

11 systems reviewed. **S**

## Current medications

- Amlodipine 5 mg oral tablet once daily **S**
- Vitamin D3 (cholecalciferol) 25 micrograms (1,000 units) oral tablet once daily, continued through the polar winters **S**

## Allergies

- No known allergy **S**

## Objective

BP 132/80 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 88.4 kg; BMI 30.6 kg/m². All vital signs are synthetic.

PHQ-2: 0. All results are synthetic.

## Immunizations given today

- Tetanus, diphtheria and acellular pertussis (Tdap) booster **S**
- Pneumococcal conjugate vaccine (PCV20), single dose **S**
- Recombinant zoster vaccine, first of two doses **S**
- Hepatitis B vaccine (HepB-CpG), first of two doses **S**
- Rabies vaccine (human diploid cell), pre-exposure prophylaxis, first of two doses **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well; weight 88.4 kg, BMI 30.6; blood pressure 132/80; pulse 72 and regular |
| Ears, nose, mouth, and throat | Ear canals clear; teeth in good repair |
| Neck | No thyroid enlargement or nodes |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Respiratory | Clear to auscultation |
| Abdomen | Soft and non-tender; no aortic pulsation felt |
| Skin | No suspicious lesions |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic adult preventive visit completed**. Health risk assessment reviewed and the prevention plan updated for an expedition beyond the reach of care. Tuberculosis blood test at intake negative. Lipids reviewed at intake; he chose no statin for now. **S**
   - Tdap, PCV20, recombinant zoster (first dose), hepatitis B (first dose) and rabies pre-exposure prophylaxis (first dose) today.
   - Second rabies dose with the nurse in one week; second hepatitis B dose at the eight-week review; second zoster dose at the pre-departure visit.
   - Fecal immunochemical test kit given; HIV, hepatitis C and hepatitis B screening drawn before the hepatitis B vaccine.
   - Next preventive visit on his return.
2. **Essential hypertension on amlodipine** (I10). Home average 131/81, close to goal. **S**
   - Continue amlodipine 5 mg; eight-week review.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure | Completed today | 132/80 mmHg; treated hypertension |
| Lipid screening and cardiovascular risk | Up to date | Lipid panel at intake; PREVENT 10-year cardiovascular risk about 6 percent; statin discussed and declined for now |
| Diabetes screening | Up to date | HbA1c 5.6% at intake; recheck on return |
| Obesity counseling | Completed today | His own plan of walking, hills and smaller portions reviewed; 2.4 kg lost |
| Colorectal cancer screening | Ordered | Never screened; fecal immunochemical test today, as colonoscopy cannot be fitted in before sailing; colonoscopy if positive |
| Lung cancer screening | Not indicated | Never smoked |
| Abdominal aortic aneurysm screening | Not indicated | For men 65 to 75 who have ever smoked |
| Prostate cancer screening | Declined | Shared decision-making at 55 to 69; he chose not to have a PSA test |
| HIV screening | Ordered | Once for adults to 65; drawn today |
| Hepatitis C screening | Ordered | Once for all adults; drawn today |
| Hepatitis B screening | Ordered | Triple panel once for all adults; drawn before the first vaccine dose |
| Latent tuberculosis screening | Up to date | Interferon-gamma release assay negative at intake, after a household contact long ago |
| Depression screening | Completed today | PHQ-2 0 |
| Unhealthy alcohol use | Up to date | AUDIT-C 3 at intake; cutting back |
| Dental examination | Up to date | Examined with films last week; a cracked filling replaced; no other work needed before sailing |
| Tetanus, diphtheria, and pertussis | Completed today | Tdap today; last booster more than ten years ago |
| Pneumococcal vaccine | Completed today | PCV20 today, recommended from 50; no further dose needed |
| Zoster vaccine | Completed today | First recombinant dose today; second before departure |
| Hepatitis B vaccine | Completed today | First HepB-CpG dose today; second in four weeks |
| Rabies pre-exposure prophylaxis | Completed today | First dose today, second in seven days; for years in the Arctic beyond the reach of rabies immune globulin |
| Influenza and COVID-19 vaccines | Up to date | Given last autumn; next doses on his return |
| RSV vaccine | Not indicated | Recommended at 50 to 74 only with conditions that raise risk; none |

## Advance care planning

Voluntary advance care planning discussion of about 25 minutes, with his consent. He named a health care agent and completed a health care proxy form; the agent is recorded in the chart and is not named here. Because he will be beyond the reach of hospital care for months at a time, he talked through what he would want if he became seriously ill in the ice: care by the ship's surgeons with the medicines on board, relief of pain and breathlessness, and no attempt at a journey that would endanger others to move him. He asked that a copy of his wishes travel with his medical record on board. The plan will be revisited on his return or after any serious illness. **S**

## Guideline basis

- Use of a Modified Preexposure Prophylaxis Vaccination Schedule to Prevent Human Rabies: Recommendations of the Advisory Committee on Immunization Practices, United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR 2022;71(18):619-627)
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Colorectal Cancer: Screening (2021), U.S. Preventive Services Task Force
- Prostate Cancer: Screening (2018), U.S. Preventive Services Task Force
- Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023 (2023), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- Universal Hepatitis B Vaccination in Adults Aged 19-59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices, United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR 2022;71(13):477-483)
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Second rabies dose with the nurse in one week. Fecal test and screening results by phone. Eight-week review with the exercise treadmill test and the second hepatitis B dose. **S**
- Next scheduled visit 1845-04-07: eight-week review: blood pressure at goal, weight, exercise treadmill test and expedition planning. **S**
